Annals of Vascular Diseases
Online ISSN : 1881-6428
Print ISSN : 1881-641X
ISSN-L : 1881-641X

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Risk and Prognosis of Upper Extremity Deep Vein Thrombosis
Yusuke EndoNaoki UnnoNaoto YamamotoMasaki SanoKazuto KatahashiTakafumi KayamaYuta YamanakaHajime TsuyukiHiroya TakeuchiKazunori Inuzuka
著者情報
ジャーナル オープンアクセス 早期公開
電子付録

論文ID: oa.23-00005

この記事には本公開記事があります。
詳細
抄録

Objectives: We aimed to investigate the clinical features of upper extremity deep vein thrombosis (UEDVT).

Methods: We retrospectively reviewed the background, thrombus site, treatment, and outcome of 76 UEDVT patients.

Results: Of the 76 UEDVT patients, 44 (57.9%) were men, and 51 (67.1%) were complicated by malignancy, 44 (57.9%) had an indwelling central vein (CV) catheter, 8 (10.5%) had concomitant pulmonary embolization (PE), and 33 (43.3%) were symptomatic. Regarding the thrombus site, the right internal jugular vein was the most common, with 30 cases (35.3%). As regards the treatment method, 53 patients (69.7%) received oral anticoagulants. In 2015, when direct oral anticoagulants (DOACs) was covered by insurance, there were 44 UEDVT cases, of which 34 (77.3%) received DOACs. Outcomes at a mean observation period of 37.5±41.5 months included 40 deaths (52.6%) with a mean survival of 16.3±21.3 months. The most common cause of death was malignancy, with 33 cases (82.5%).

Conclusion: In the background of UEDVT, the combination of indwelling CV catheter placement and malignancy was frequently observed. While the risk of recurrence or PE complications is low, the prognosis of UEDVT complicated by malignancy is extremely poor.

著者関連情報
© 2023 The Editorial Committee of Annals of Vascular Diseases. This article is distributed under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided the credit of the original work, a link to the license, and indication of any change are properly given, and the original work is not used for commercial purposes. Remixed or transformed contributions must be distributed under the same license as the original.

This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
https://creativecommons.org/licenses/by-nc-sa/4.0/
feedback
Top